Literature DB >> 23761182

Informative censoring in relative survival.

Anamarija Rebolj Kodre1, Maja Pohar Perme.   

Abstract

With changing the age distribution at the time of cancer diagnosis, the administrative censoring due to study end may be informative. This problem has been mentioned frequently in the relative survival field, and an estimator aiming to correct this problem has been developed. In this paper, we review the existing methods for estimation in relative survival, demonstrate their deficiencies, and propose weighting to correct both the recently introduced net survival estimator and the Ederer I estimator. Using simulations and real cancer registry data, we evaluate the magnitude of the informative censoring problem. We clarify the assumptions behind the reviewed methods and provide guidance to their usage in practice.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  informative censoring; inverse probability weighting; net survival; relative survival ratio

Mesh:

Year:  2013        PMID: 23761182     DOI: 10.1002/sim.5877

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  Comparison of different approaches to estimating age standardized net survival.

Authors:  Paul C Lambert; Paul W Dickman; Mark J Rutherford
Journal:  BMC Med Res Methodol       Date:  2015-08-15       Impact factor: 4.615

2.  On standardized relative survival.

Authors:  Peter Sasieni; Adam R Brentnall
Journal:  Biometrics       Date:  2016-08-23       Impact factor: 2.571

3.  Correcting for misclassification and selection effects in estimating net survival in clinical trials.

Authors:  Juste Aristide Goungounga; Célia Touraine; Nathalie Grafféo; Roch Giorgi
Journal:  BMC Med Res Methodol       Date:  2019-05-16       Impact factor: 4.615

4.  Correcting inaccurate background mortality in excess hazard models through breakpoints.

Authors:  Robert Darlin Mba; Juste Aristide Goungounga; Nathalie Grafféo; Roch Giorgi
Journal:  BMC Med Res Methodol       Date:  2020-10-29       Impact factor: 4.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.